Product Description
Amoxicillin is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis (infection of the airway tubes leading to the lungs); and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a685001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Skin Ulcer | Duodenal Ulcer | Helicobacter Infections | Respiratory Tract Infections | Urinary Tract Infections | Pharyngitis | Tonsillitis | Helicobacter Infections
Known Adverse Events: Diarrhea | Headache | Hypertension | Abdominal Pain | Dysgeusia | Pain Unspecified | Nasopharyngitis | Pharyngitis | Candidiasis | Candidiasis, Vulvovaginal
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Benin, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Kenya, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|COVID-19|Clostridium Infections|Diarrhea|Febrile Neutropenia|Fractures, Open|Helicobacter Infections|Influenza, Human|Intestinal Diseases|Pneumonia|Respiratory Tract Infections|Urinary Tract Infections|Vaginosis, Bacterial
Phase 2: Buruli Ulcer|Diverticulitis|Pyelonephritis
Phase 1: Communicable Diseases|Duodenal Diseases|Duodenal Ulcer|Esophagitis|Short Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DURATIOM | P3 |
Unknown Status |
Fractures, Open |
2027-12-31 |
|
| BLMs4BU | P2 |
Recruiting |
Buruli Ulcer |
2026-05-31 |
|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|COVID-19|Influenza, Human |
2026-02-01 |
|
| DIREBIOT | P2 |
Unknown Status |
Diverticulitis |
2025-12-31 |